Eczacıbaşı-Monrol Nuclear Products will provide lutetium-177 (Lu-177) to Telix Pharmaceuticals Limited for a phase II clinical trial of its Starlite 2 renal cancer therapy medication TLX250 (Lu-177 DOTA-girentuximab).
The trial is being conducted at Memorial Sloan Kettering Cancer Center in New York City. It is evaluating the efficacy of TLX250-targeted radiation in conjunction with the anti-PD-11 immunotherapy Opdivo2 (nivolumab) for aggressive kidney cancer. TLX250 targets a protein commonly found in patients likely to have limited response to cancer immunotherapy, Monrol and Telix said.
Memorial Sloan Kettering has financial interests in Telix, according to the two firms.
